Integration of published information into a resistance-associated mutation database for mycobacterium tuberculosis

Journal of Infectious Diseases

Volumn 211, Issue , 2015, Pages S50-S57

  Salamon, Hugh ^a   Yamaguchi, Ken D ^a   Cirillo, Daniela M ^b   Miotto, Paolo ^b   Schito, Marco ^c   Posey, James ^d   Starks, Angela M ^d   Niemann, Stefan ^e   Alland, David ^f   Hanna, Debra ^g   Aviles, Enrique ^g   Perkins, Mark D ^h   Dolinger, David L ^h  

^a Knowledge Synthesis   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e RESEARCH CENTER BORSTEL   (Germany)

^f RUTGERS UNIVERSITY   (United States)

^g CRITICAL PATH INSTITUTE   (United States)

^h FIND ^*  (Switzerland)

Author keywords

Database; Drug resistance; Drug susceptibility testing; Genomic sequencing; Resistance associated mutations; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENE SEQUENCE; GENETIC DATABASE; GENOTYPE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG EFFECTS; GENETICS; HUMAN; MICROBIOLOGY; MUTATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DATABASES, GENETIC; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84983786096     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu816     Document Type: Article

References (17)

1. Jain A, Mondal R. Extensively drug-resistant tuberculosis: current challenges and threats. FEMS Immunol Med Microbiol 2008; 53: 145-50.
2. Van Deun A, Wright A, Zignol M, Weyer K, Rieder HL. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011; 15:116-24.
3. Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, Ridderhof JC. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J Clin Microbiol 2012; 50: 1233-9.
4. Jiang G-L, Chen X, Song Y, Zhao Y, Huang H, Kam KM. First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China. Int J Tuberc Lung Dis 2013; 17:1491-4.
5. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
6. Catanho M, Mascarenhas D, DegraveW, de Miranda AB. GenoMycDB: a database for comparative analysis of mycobacterial genes and genomes. Genet Mol Res GMR 2006; 5:115-26.
7. Stucki D, Gagneux S. Single nucleotide polymorphisms in Mycobacterium tuberculosis and the need for a curated database. Tuberc Edinb Scotl 2013; 93:30-9.
8. Lu JT, Campeau PM, Lee BH. Genotype-phenotype correlation- promiscuity in the era of next-generation sequencing. N Engl J Med 2014; 371:593-6.
9. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6:e2.
10. Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:2032-41.
11. Casali N, Nikolayevskyy V, Balabanova Y, et al. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res 2012; 22:735-45.
12. Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol 2013; 62 (Pt 1):108-13.
13. Rodwell TC, Valafar F, Douglas J, et al. Predicting extensively drugresistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol 2014; 52:781-9.
14. Lin S-YG, Rodwell TC, Victor TC, et al. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 2014; 52:475-82.
15. Miotto P, Cabibbe AM, Feuerriegel S, et al. Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study. MBio 2014; 5:e01819-14.
16. Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67:819-31.
17. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PloS One 2012; 7:e33275.